Bionano Genomics Reports Third Quarter 2026 Financial Results
Bionano Genomics announced its financial results for the third quarter ended September 30, 2026, reporting $8.3 million in total revenue and a 12% year-over-year increase.
Stocks · News reference
Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies — myelodysplastic
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bionano Genomics announced its financial results for the third quarter ended September 30, 2026, reporting $8.3 million in total revenue and a 12% year-over-year increase.
Bionano Genomics, Inc. announced it will host a conference call and live webcast on November 10, 2026, to discuss its third quarter 2026 financial results and corporate progress.
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
Filed: 2026-09-14 AccNo: 0001411690-26-000046 Size: 13 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular